EyeGene (Korea) Today
| 185490 Stock | KRW 2,590 105.00 3.90% |
Performance0 of 100
| Odds Of DistressLess than 24
|
EyeGene is trading at 2590.00 as of the 31st of January 2025, a 3.9 percent decrease since the beginning of the trading day. The stock's open price was 2695.0. EyeGene has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea. The company has 10.99 M outstanding shares. More on EyeGene
Moving together with EyeGene Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
EyeGene Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. EyeGene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding EyeGene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Won Yoo |
| Business Concentration | Biotechnology (View all Sectors) |
EyeGene (185490) is traded on KOSDAQ in Korea and employs 63 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 69.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate EyeGene's market, we take the total number of its shares issued and multiply it by EyeGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. EyeGene has 10.99 M outstanding shares.
EyeGene has accumulated about 1.04 B in cash with (30 B) of positive cash flow from operations.
Check EyeGene Probability Of Bankruptcy
Ownership AllocationEyeGene retains a total of 10.99 Million outstanding shares. EyeGene shows 9.7 percent of its outstanding shares held by insiders and 0.3 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check EyeGene Ownership Details
EyeGene Risk Profiles
Although EyeGene's alpha and beta are two of the key measurements used to evaluate EyeGene's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.48 | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.2 | |||
| Risk Adjusted Performance | (0.04) |
EyeGene Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in EyeGene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
EyeGene Corporate Directors
Other Information on Investing in EyeGene Stock
EyeGene financial ratios help investors to determine whether EyeGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EyeGene with respect to the benefits of owning EyeGene security.